Saturday, July 2, 2022
wellness India Expo
Home Tags Novartis

Tag: Novartis

Decoding the future of PharmaTech & Patient Data Protection

Leaders from Microsoft, Novartis and Roche Group deliberate on the collaboration of pharma and technology

Novartis India extends access to its medicines in India by signing...

The arrangement brings together the manufacturing and development synergies of Novartis India Limited with the sales and distribution strengths of Dr. Reddy’s Laboratories

Novartis renews WHO medicine donation pledge with aim of ending leprosy

Novartis leprosy medicine donation program with WHO extended to 2025. Program has already treated over 7 million patients since 2000..........................

Novartis’s 5 year long clinical study on type 2 diabetes treatment...

Early combination treatment strategy with vildagliptin and metformin was superior to the standard of care in newly diagnosed type 2 diabetes patients. The landmark VERIFY study is the first to investigate the long-term clinical benefits of this early combination strategy in type 2 diabetes...................

Alcon debuts as independent, publicly traded company

After the company completed its separation from Novartis, it has begun trading on SIX Swiss Exchange and New York Stock Exchange...............

Aurobindo Pharma acquires Sandoz’s dermatology, oral solid business in US for...

Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion. Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars...……..

Post NHS approval, sky is the limit for Novartis’ CAR-T therapy:...

According to GlobalData forecasts, the Novartis CAR-T therapy, Kymriah is expected to hit over $1billion sales revenue by 2023 in the US alone......……….

Pricing adjustments for CAR-T therapies likely to take place in 2018,...

A fairly comprehensive study reported in February 2018 on the Health Affairs Blog claims that Novartis could lower the price of Kymriah by two-thirds and still achieve a profit..................

Digital health can prove cost effective for drug development, says GlobalData

As per the leading data and analytics firm, GlobalData, the research and development in the pharmaceutical and drug companies could get a major boost due to use of artificial intelligence and other digital technologies................

Novartis’ Scapho shows pioneering 4-year data in preventing Ankylosing Spondylitis progression

For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Scapho have no radiographic progression of the spine at 4 years.......